$AMGN

AMGEN Inc

$AMGN

AMGEN Inc

Past 12mo:26mentions3voices

All voices7 calls since Nov 2025show all

Loading price chart…

About this stock

$AMGN has been mentioned 26 times over a 12-month period spanning from September 4, 2025 to May 8, 2026 by three distinct FinTwit voices in the biotech category. Jacob Plieth (@jacobplieth) leads engagement with 17 mentions, followed by Adam Feuerstein (@adamfeuerstein) with 9 mentions, and Jason Luongo (@jasonl_capital) with 1 mention. The discussions have covered regulatory matters, clinical trial developments, and collaborative initiatives involving the company.

AI-generated from tracked posts · updated Aug 17, 2026

Frequently asked

Related stocks

$ALLOAllogene Therapeutics

$ARVNArvinas

$ATRAAtara Biotherapeutics

$BNTXBioNTech SE

Recent calls

7 calls

@adamfeuersteinApr 28, 2026 · 7:29 PM

FDA launches effort with $AZN $AMGN to speed up clinical trials, using AI https://t.co/k4LjxnDLmq via @LizzyLaw_

Open on X

@jacobpliethMar 18, 2026 · 10:17 AM

$AMGN's likely discontinued anti-CCR8 MAb #AACR26

Open on X

@adamfeuersteinFeb 3, 2026 · 9:10 PM

$AMGN Tavneos update. FDA wants it pulled from the market. On January 16, 2026, the U.S. Food and Drug Administration (FDA) requested that ChemoCentryx voluntarily withdraw TAVNEOS from the U.S. market. The FDA raised concerns about the process followed by ChemoCentryx to re-adjudicate primary endpoint results for 9 of the 331 patients in its pivotal clinical trial. Hepatotoxicity, which is a known infrequent risk of TAVNEOS treatment for AAV, was also raised in the context of the benefit-risk profile of the medicine. Amgen is not aware of any issue with the underlying patient data from the ChemoCentryx clinical trial. And after review of the relevant clinical data and years of real-world evidence, Amgen is confident that TAVNEOS demonstrates effectiveness and a favorable benefit–risk profile. On January 28, 2026, following FDA regulatory process, Amgen informed the Agency that it did not intend to withdraw TAVNEOS from the market. Amgen is evaluating next steps with the FDA to determine a path forward, while keeping patient safety, needs and support at the forefront.

Open on X

@adamfeuersteinFeb 2, 2026 · 12:52 PM

Another OX40 update, and it's not good. On an analyst call Sunday, Kyowa Kirin disclosed a case of Karposi's sarcoma with rocatinlimab in a "high risk" patient, according to a Jefferies note. Recall, last week, $AMGN returned roca to Kyowa.

Open on X

@adamfeuersteinJan 30, 2026 · 2:31 PM

And now $AMGN returns its OX40 drug candidate rocatinlimab to Kyowa.

Open on X

@adamfeuersteinJan 23, 2026 · 12:23 PM

Perhaps I am over-reacting, but doesn't the reported case of Kaposi's sarcoma in the $SNY amlitelimab atopic dermatitis study basically end any hope for the entire OX40 drug class? $AMGN included. Why would any patient or physician take the risk with an OX40 drug when there are so many other better treatment options?

Open on X

@adamfeuersteinNov 8, 2025 · 3:41 PM

#AHA25 reporting all weekend Amgen’s $AMGN cholesterol shot prevented first heart attacks and strokes, more detailed data affirm https://t.co/1RX6TrfU6l via @cooney_liz

Open on X

Who mentions $AMGN most on Surfaced?

@jacobplieth (Jacob Plieth) mentions $AMGN most — 17 mentions in the past 12 months.

When was $AMGN first mentioned on Surfaced?

The earliest tracked mention of $AMGN in the Surfaced archive was on Sep 4, 2025.

How many voices track $AMGN?

3 FinTwit voices have mentioned $AMGN 26 times in the past 12 months.

What kind of voices mention $AMGN most?

$AMGN is mentioned most by Biotech voices on Surfaced.